Pub Date : 2024-01-01Epub Date: 2024-09-23DOI: 10.5114/pg.2024.143439
Grażyna Piotrowicz, Jacek Kot, Andrzej Babicki, Piotr Banaszkiewicz, Adam Piotrowicz, Magdalena Rzeszutek, Agata Rudnik, Piotr Zientara, Joanna Adamska-Mieruszewska, Grażyna Rydzewska
Introduction: Crohn's disease is a chronic, complex inflammatory disorder of the gastrointestinal tract. Among its most challenging complications are perianal fistulas.
Aim: This study aims to explore the efficacy of hyperbaric oxygen therapy (HBOT) in reducing the activity of perianal fistulas in Crohn's disease patients.
Material and methods: This study enrolled patients diagnosed with Crohn's disease-associated perianal fistulas, with a disease duration of at least 3 years. Participants underwent HBOT in conjunction with standard medical therapy. The therapeutic effects were assessed at predetermined intervals using the Crohn's Disease Activity Index (CDAI), and laboratory parameters including faecal calprotectin levels, C-reactive protein (CRP) activity, serum iron concentration, and peripheral blood haemoglobin levels. Additionally, the Simple Endoscopic Score for Crohn's Disease (SESCD) and the Perianal Disease Activity Index (PDAI) were employed for evaluation.
Results: The adjunctive use of HBOT with conventional therapy yielded significant clinical improvements in patients with Crohn's disease complicated by perianal fistulas. This was shown by an 81.8% improvement in CDAI scores and a 54.5% clinical remission rate, as determined by SESCD and PDAI. Notably, the beneficial effects of HBOT on SESCD, PDAI, and faecal calprotectin levels were statistically significant and persisted for 6 weeks post-HBOT, with sustained improvements observed in a follow-up assessment approximately 9 months after treatment.
Conclusions: The findings of this study suggest that HBOT may be a viable therapeutic adjunct in the management of complex cases of Crohn's disease, particularly those with recurrent symptoms and limited responsiveness to conventional treatments. HBOT demonstrated potential in improving clinical outcomes and achieving remission rates exceeding 50%, indicating its promise as a treatment modality in this patient population.
{"title":"The effects of hyperbaric treatment on perianal fistula activity in patients with Crohn's disease.","authors":"Grażyna Piotrowicz, Jacek Kot, Andrzej Babicki, Piotr Banaszkiewicz, Adam Piotrowicz, Magdalena Rzeszutek, Agata Rudnik, Piotr Zientara, Joanna Adamska-Mieruszewska, Grażyna Rydzewska","doi":"10.5114/pg.2024.143439","DOIUrl":"10.5114/pg.2024.143439","url":null,"abstract":"<p><strong>Introduction: </strong>Crohn's disease is a chronic, complex inflammatory disorder of the gastrointestinal tract. Among its most challenging complications are perianal fistulas.</p><p><strong>Aim: </strong>This study aims to explore the efficacy of hyperbaric oxygen therapy (HBOT) in reducing the activity of perianal fistulas in Crohn's disease patients.</p><p><strong>Material and methods: </strong>This study enrolled patients diagnosed with Crohn's disease-associated perianal fistulas, with a disease duration of at least 3 years. Participants underwent HBOT in conjunction with standard medical therapy. The therapeutic effects were assessed at predetermined intervals using the Crohn's Disease Activity Index (CDAI), and laboratory parameters including faecal calprotectin levels, C-reactive protein (CRP) activity, serum iron concentration, and peripheral blood haemoglobin levels. Additionally, the Simple Endoscopic Score for Crohn's Disease (SESCD) and the Perianal Disease Activity Index (PDAI) were employed for evaluation.</p><p><strong>Results: </strong>The adjunctive use of HBOT with conventional therapy yielded significant clinical improvements in patients with Crohn's disease complicated by perianal fistulas. This was shown by an 81.8% improvement in CDAI scores and a 54.5% clinical remission rate, as determined by SESCD and PDAI. Notably, the beneficial effects of HBOT on SESCD, PDAI, and faecal calprotectin levels were statistically significant and persisted for 6 weeks post-HBOT, with sustained improvements observed in a follow-up assessment approximately 9 months after treatment.</p><p><strong>Conclusions: </strong>The findings of this study suggest that HBOT may be a viable therapeutic adjunct in the management of complex cases of Crohn's disease, particularly those with recurrent symptoms and limited responsiveness to conventional treatments. HBOT demonstrated potential in improving clinical outcomes and achieving remission rates exceeding 50%, indicating its promise as a treatment modality in this patient population.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 3","pages":"321-332"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-11-17DOI: 10.5114/pg.2023.132932
Mohamed Ali El-Nady, Nour Eldeen El-Hefny, Hayam Fathy, Wageeh Ali, Ahmed Mohammed Ashmawy
Introduction: Inflammatory bowel disease patients are exposed to frequent procedures and hospital admissions as well as recurrent need for radiological examinations with a high risk of exposure to radiation and contrast.
Aim: Our objective was to evaluate the role of a combination of both intestinal ultrasound (IUS) and colour Doppler with different parameters for monitoring changes in inflammation over time and to reveal their potential role in the assessment of response to biologic therapy in inflammatory bowel disease (IBD) patients.
Material and methods: Before the induction of biological therapy, IUS together with colour Doppler of the intestine was conducted. Response to therapy was defined following the international guidelines.
Results: A total of 45 patients with histopathological diagnosis of IBD were enrolled in the study. All patients received biological therapy and were assessed for response after 3 months. Out of those patients, 34 (75.6%) had good response while 11 (24.4%) failed to respond to the treatment. Our findings point to a strong association between bowel wall thickening (BWT) and serum albumin, erythrocyte sedimentation rate (ESR), and c-reactive protein (CRP). The overall sensitivity of IUS varied from 54 to 93% when evaluating bowel affection, with a specificity of 97-100%, in comparison to our results, which showed a sensitivity of 64-74% and specificity of 79-82%. Doppler parameters could predict the response to the biologic therapy in IBD patients.
Conclusions: Intestinal ultrasound and colour Doppler provide a safe, non-invasive way to monitor changes in inflammation and blood flow in the digestive tract.
{"title":"The role of intestinal ultrasound with colour Doppler in predicting the response to biologic therapy in inflammatory bowel disease patients.","authors":"Mohamed Ali El-Nady, Nour Eldeen El-Hefny, Hayam Fathy, Wageeh Ali, Ahmed Mohammed Ashmawy","doi":"10.5114/pg.2023.132932","DOIUrl":"10.5114/pg.2023.132932","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory bowel disease patients are exposed to frequent procedures and hospital admissions as well as recurrent need for radiological examinations with a high risk of exposure to radiation and contrast.</p><p><strong>Aim: </strong>Our objective was to evaluate the role of a combination of both intestinal ultrasound (IUS) and colour Doppler with different parameters for monitoring changes in inflammation over time and to reveal their potential role in the assessment of response to biologic therapy in inflammatory bowel disease (IBD) patients.</p><p><strong>Material and methods: </strong>Before the induction of biological therapy, IUS together with colour Doppler of the intestine was conducted. Response to therapy was defined following the international guidelines.</p><p><strong>Results: </strong>A total of 45 patients with histopathological diagnosis of IBD were enrolled in the study. All patients received biological therapy and were assessed for response after 3 months. Out of those patients, 34 (75.6%) had good response while 11 (24.4%) failed to respond to the treatment. Our findings point to a strong association between bowel wall thickening (BWT) and serum albumin, erythrocyte sedimentation rate (ESR), and c-reactive protein (CRP). The overall sensitivity of IUS varied from 54 to 93% when evaluating bowel affection, with a specificity of 97-100%, in comparison to our results, which showed a sensitivity of 64-74% and specificity of 79-82%. Doppler parameters could predict the response to the biologic therapy in IBD patients.</p><p><strong>Conclusions: </strong>Intestinal ultrasound and colour Doppler provide a safe, non-invasive way to monitor changes in inflammation and blood flow in the digestive tract.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"16 4","pages":"416-422"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-03-14DOI: 10.5114/pg.2024.136246
Maxim Tszyan
Introduction: One of the urgent tasks of modern healthcare is the development of measures aimed at preventing obesity in the able-bodied population, including in the Republic of Kazakhstan, which would reduce economic losses and increase the coefficient of life expectancy in the population.
Aim: To identify measures for the early prevention of excess weight, obesity, and carbohydrate metabolism disorders in the able-bodied population at an industrial facility in Kazakhstan.
Material and methods: The study involved 662 people (574 men and 88 women) aged 19 to 64 years. The subjects were divided into 2 groups: the main group - persons with obesity (242 people) and the control group - relatively healthy persons (422 people). The diagnosis of obesity was made based on the medical history of a patient, external examination, and physical, laboratory, and instrumental assessment.
Results: Three main factors influencing the development of obesity have been identified: a significant level of inactivity; serum glucose; the presence of comorbidities. Other factors (gender and age, smoking) do not have a significant effect on the increase in the body mass index of persons working at an industrial facility.
Conclusions: Accordingly, a priority in the prevention of obesity is a healthy lifestyle, involving regular physical activity and a healthy balanced diet.
{"title":"Prevention of obesity and carbohydrate metabolism disorders in the population at an industrial facility.","authors":"Maxim Tszyan","doi":"10.5114/pg.2024.136246","DOIUrl":"https://doi.org/10.5114/pg.2024.136246","url":null,"abstract":"<p><strong>Introduction: </strong>One of the urgent tasks of modern healthcare is the development of measures aimed at preventing obesity in the able-bodied population, including in the Republic of Kazakhstan, which would reduce economic losses and increase the coefficient of life expectancy in the population.</p><p><strong>Aim: </strong>To identify measures for the early prevention of excess weight, obesity, and carbohydrate metabolism disorders in the able-bodied population at an industrial facility in Kazakhstan.</p><p><strong>Material and methods: </strong>The study involved 662 people (574 men and 88 women) aged 19 to 64 years. The subjects were divided into 2 groups: the main group - persons with obesity (242 people) and the control group - relatively healthy persons (422 people). The diagnosis of obesity was made based on the medical history of a patient, external examination, and physical, laboratory, and instrumental assessment.</p><p><strong>Results: </strong>Three main factors influencing the development of obesity have been identified: a significant level of inactivity; serum glucose; the presence of comorbidities. Other factors (gender and age, smoking) do not have a significant effect on the increase in the body mass index of persons working at an industrial facility.</p><p><strong>Conclusions: </strong>Accordingly, a priority in the prevention of obesity is a healthy lifestyle, involving regular physical activity and a healthy balanced diet.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"33-45"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-11-27DOI: 10.5114/pg.2023.133222
Paweł Kurzelowski, Maciej Pluskiewicz, Aleksandra Pilśniak, Agnieszka Jarosińska, Michał Holecki
{"title":"Recurrent tetany in a male patient with short bowel syndrome and Crohn's disease.","authors":"Paweł Kurzelowski, Maciej Pluskiewicz, Aleksandra Pilśniak, Agnieszka Jarosińska, Michał Holecki","doi":"10.5114/pg.2023.133222","DOIUrl":"https://doi.org/10.5114/pg.2023.133222","url":null,"abstract":"","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"97-98"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-09-23DOI: 10.5114/pg.2024.143165
Tomasz Klimczak, Jacek Śmigielski
{"title":"Direct peroral cholangioscopy combined with argon plasma and radio-frequency ablation in restoring the patency of a self-expandable metal stent.","authors":"Tomasz Klimczak, Jacek Śmigielski","doi":"10.5114/pg.2024.143165","DOIUrl":"10.5114/pg.2024.143165","url":null,"abstract":"","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"16 4","pages":"460-462"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regulated cell death is a fundamental biological process that plays a crucial role in maintaining tissue homeostasis and eliminating damaged or unnecessary cells. Ferroptosis is an iron-dependent process, characterized by the accumulation of oxidized and damaged lipids, which leads to programmed cell death. Among the ferroptotic pathway genes regulating this process, GPX4, TFRC, ACSL4, FSP1, SLC7A11, and PROM2 could be considered. There are many well-known ferroptotic pathway regulators, which are discussed in this compact review. Cells with tissues of different origin display sensitive or resistant phenotypes to such regulators. In some cases, unexpected changes during cell treatment occurred, suggesting the possibility of regulating the death pathway. We assumed that possible changing of ferro-sensitivity to ferro-resistance in cells, especially in colorectal cancer cell lines, is responded for induced chemoresistance. Using novel techniques, such as CRISPR/Cas-9 genome editing, an induced phenotype "switching" is possible.
{"title":"Resistance to death pathway induction as a potential targeted therapy in CRISPR/Cas-9 knock-out colorectal cancer cell lines.","authors":"Malgorzata Adamiec-Organisciok, Magdalena Wegrzyn, Lukasz Cienciala, Ngoni Magate, Magdalena Skonieczna, Joanna Nackiewicz","doi":"10.5114/pg.2024.134872","DOIUrl":"https://doi.org/10.5114/pg.2024.134872","url":null,"abstract":"<p><p>Regulated cell death is a fundamental biological process that plays a crucial role in maintaining tissue homeostasis and eliminating damaged or unnecessary cells. Ferroptosis is an iron-dependent process, characterized by the accumulation of oxidized and damaged lipids, which leads to programmed cell death. Among the ferroptotic pathway genes regulating this process, GPX4, TFRC, ACSL4, FSP1, SLC7A11, and PROM2 could be considered. There are many well-known ferroptotic pathway regulators, which are discussed in this compact review. Cells with tissues of different origin display sensitive or resistant phenotypes to such regulators. In some cases, unexpected changes during cell treatment occurred, suggesting the possibility of regulating the death pathway. We assumed that possible changing of ferro-sensitivity to ferro-resistance in cells, especially in colorectal cancer cell lines, is responded for induced chemoresistance. Using novel techniques, such as CRISPR/Cas-9 genome editing, an induced phenotype \"switching\" is possible.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"112-120"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-12-02DOI: 10.5114/pg.2024.142141
Rasha I Salama, Salwa Tawfik, Mohamed H Emara, Abeer H Abdelkader
Introduction: Abdominal bloating is a prevalent condition that affects up to 30% of the population.
Aim: Investigate the impact of cefixime and probiotics on the bloating sensation among patients with functional abdominal bloating (FAB).
Material and methods: Out of 763 patients with bloating, 122 patients were diagnosed with FAB. Group I (n = 40) were treated with a combination of non-activated herbal charcoal and silicone dioxide with dimethylpolysiloxane (conventional treatment group); group II (n = 41) were treated by the same lines as in group I with the addition of cefixime 400 mg once daily for 6 days; and group III (n = 41) were treated by the same lines given to group I with the addition of a probiotic formulation harbouring the probiotic strain Lactobacillus helveticus candisis for 2 weeks. All patients were evaluated by history taking, clinical examination, laboratory assessment, relevant imaging, and symptom questionnaire before and by the end of treatment.
Results: The prevalence of FAB was 15.9% (122/763). The majority were females (58.1%). Patients treated with probiotics and cefixime reported significant improvement in the sense of bloating and the visible abdominal distension in comparison to conventional treatment (p = 0.008 and < 0.001, respectively). Abdominal pain, belching, bowel habit change, and nausea improved and were comparable among the 3 groups by the end of treatment. No adverse events related to the used medications were observed.
Conclusions: Cefixime and probiotics exert significant improvement in the subjective sensation of bloating and objective abdominal distension among patients with FAB in comparison to conventional anti-flatulence therapy.
{"title":"Impact of cefixime and probiotics on functional abdominal bloating: a pilot study.","authors":"Rasha I Salama, Salwa Tawfik, Mohamed H Emara, Abeer H Abdelkader","doi":"10.5114/pg.2024.142141","DOIUrl":"10.5114/pg.2024.142141","url":null,"abstract":"<p><strong>Introduction: </strong>Abdominal bloating is a prevalent condition that affects up to 30% of the population.</p><p><strong>Aim: </strong>Investigate the impact of cefixime and probiotics on the bloating sensation among patients with functional abdominal bloating (FAB).</p><p><strong>Material and methods: </strong>Out of 763 patients with bloating, 122 patients were diagnosed with FAB. Group I (<i>n</i> = 40) were treated with a combination of non-activated herbal charcoal and silicone dioxide with dimethylpolysiloxane (conventional treatment group); group II (<i>n</i> = 41) were treated by the same lines as in group I with the addition of cefixime 400 mg once daily for 6 days; and group III (<i>n</i> = 41) were treated by the same lines given to group I with the addition of a probiotic formulation harbouring the probiotic strain <i>Lactobacillus helveticus candisis</i> for 2 weeks. All patients were evaluated by history taking, clinical examination, laboratory assessment, relevant imaging, and symptom questionnaire before and by the end of treatment.</p><p><strong>Results: </strong>The prevalence of FAB was 15.9% (122/763). The majority were females (58.1%). Patients treated with probiotics and cefixime reported significant improvement in the sense of bloating and the visible abdominal distension in comparison to conventional treatment (<i>p</i> = 0.008 and < 0.001, respectively). Abdominal pain, belching, bowel habit change, and nausea improved and were comparable among the 3 groups by the end of treatment. No adverse events related to the used medications were observed.</p><p><strong>Conclusions: </strong>Cefixime and probiotics exert significant improvement in the subjective sensation of bloating and objective abdominal distension among patients with FAB in comparison to conventional anti-flatulence therapy.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"16 4","pages":"408-415"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction As one of the most common malignant tumours, liver cancer is difficult to detect in the early stage, with strong metastasis and poor prognosis. Anti-silencing function protein 1 was originally discovered in yeast as a histone H3-H4 chaperone, and studies have shown that ASF1B may be a target for inhibiting the growth of hepatocellular carcinoma cells. Aim To evaluate the diagnostic and prognostic significance of ASF1B expression in human LIHC on the basis of TCGA data. Material and methods A meta-analysis revealed that high ASF1B expression was strongly associated with better overall survival. A comprehensive pan-cancer analysis of 33 human cancers revealed the immunotherapeutic value of ASF1B. Results In this study, we observed a significant upregulation of ASF1B expression in LIHC samples compared to non-cancer samples. Clinical analysis showed that high expression of ASF1B was associated with age, tumour status, and clinical stage. Survival analysis showed that patients with high ASF1B expression had worse overall survival and progression-free survival than patients with low ASF1B expression. The AUCs of the 1-year, 3-year, and 5-year survival-related ROC curves were 0.672, 0.590, and 0.591, respectively. Conclusions Our study shows that ASF1B may provide new ideas for the diagnosis and prognosis of liver cancer patients, as well as providing a new direction for the application of ASF1B in tumour immunotherapy.
{"title":"Identification of ASF1B as a prognostic marker for liver cancer by meta-analysis and its immune value revealed by a comprehensive pan-cancer analysis of 33 human cancersrevealed by a comprehensive pan-cancer analysis of 33 human cancers","authors":"Yiyang Chen, Wanbang Zhou, Yiju Gong, Xi Ou","doi":"10.5114/pg.2023.124423","DOIUrl":"https://doi.org/10.5114/pg.2023.124423","url":null,"abstract":"Introduction As one of the most common malignant tumours, liver cancer is difficult to detect in the early stage, with strong metastasis and poor prognosis. Anti-silencing function protein 1 was originally discovered in yeast as a histone H3-H4 chaperone, and studies have shown that ASF1B may be a target for inhibiting the growth of hepatocellular carcinoma cells. Aim To evaluate the diagnostic and prognostic significance of ASF1B expression in human LIHC on the basis of TCGA data. Material and methods A meta-analysis revealed that high ASF1B expression was strongly associated with better overall survival. A comprehensive pan-cancer analysis of 33 human cancers revealed the immunotherapeutic value of ASF1B. Results In this study, we observed a significant upregulation of ASF1B expression in LIHC samples compared to non-cancer samples. Clinical analysis showed that high expression of ASF1B was associated with age, tumour status, and clinical stage. Survival analysis showed that patients with high ASF1B expression had worse overall survival and progression-free survival than patients with low ASF1B expression. The AUCs of the 1-year, 3-year, and 5-year survival-related ROC curves were 0.672, 0.590, and 0.591, respectively. Conclusions Our study shows that ASF1B may provide new ideas for the diagnosis and prognosis of liver cancer patients, as well as providing a new direction for the application of ASF1B in tumour immunotherapy.","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"6 1","pages":"249 - 265"},"PeriodicalIF":1.3,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70475058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Héctor Adrián Díaz Hernández, José Elihú Cuevas Castillejos, Godolfino Miranda Zazueta, Adriana Fabiola Romano Munive, Francisco Valdovinos Andraca
Introduction: The COVID-19 pandemic caused many changes in gastrointestinal endoscopy units.
Aim: To describe the changes that occurred in a gastrointestinal endoscopy unit of a hybrid hospital during the COVID-19 pandemic.
Material and methods: We performed a retrospective study of endoscopies performed in the first year of the COVID-19 pandemic. We collected and described the data of interest to the study, which is presented with numbers and percentages or measures of central tendency and dispersion as appropriate. Fisher's exact test or the χ2 test were used as appropriate.
Results: A total of 507 procedures were performed. There was a 92.5% reduction in the performance of endoscopic procedures. In all, 77 (15%) procedures were performed on patients with COVID-19. The most frequent procedures were esophagogastroduodenoscopy (EGD), colonoscopy, and endoscopic retrograde cholangiopancreatography (ERCP). The main indications were gastrointestinal bleeding, placement of enteral accesses, and alterations in the biliary and pancreatic ducts. Of these, 37 (48%) were therapeutic. Patients with COVID-19 were more susceptible to the development of complications.
Conclusions: During the first year of the COVID-19 pandemic, the number of endoscopic procedures performed decreased significantly. The procedures most often required were EGD, colonoscopy, and ERCP, mainly indicated by gastrointestinal bleeding, placement of enteral accesses, and alterations of the bile and pancreatic ducts.
{"title":"Characteristics of the endoscopic procedures performed in a hybrid tertiary-level hospital during the first year of the COVID-19 pandemic.","authors":"Héctor Adrián Díaz Hernández, José Elihú Cuevas Castillejos, Godolfino Miranda Zazueta, Adriana Fabiola Romano Munive, Francisco Valdovinos Andraca","doi":"10.5114/pg.2022.118136","DOIUrl":"https://doi.org/10.5114/pg.2022.118136","url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 pandemic caused many changes in gastrointestinal endoscopy units.</p><p><strong>Aim: </strong>To describe the changes that occurred in a gastrointestinal endoscopy unit of a hybrid hospital during the COVID-19 pandemic.</p><p><strong>Material and methods: </strong>We performed a retrospective study of endoscopies performed in the first year of the COVID-19 pandemic. We collected and described the data of interest to the study, which is presented with numbers and percentages or measures of central tendency and dispersion as appropriate. Fisher's exact test or the χ<sup>2</sup> test were used as appropriate.</p><p><strong>Results: </strong>A total of 507 procedures were performed. There was a 92.5% reduction in the performance of endoscopic procedures. In all, 77 (15%) procedures were performed on patients with COVID-19. The most frequent procedures were esophagogastroduodenoscopy (EGD), colonoscopy, and endoscopic retrograde cholangiopancreatography (ERCP). The main indications were gastrointestinal bleeding, placement of enteral accesses, and alterations in the biliary and pancreatic ducts. Of these, 37 (48%) were therapeutic. Patients with COVID-19 were more susceptible to the development of complications.</p><p><strong>Conclusions: </strong>During the first year of the COVID-19 pandemic, the number of endoscopic procedures performed decreased significantly. The procedures most often required were EGD, colonoscopy, and ERCP, mainly indicated by gastrointestinal bleeding, placement of enteral accesses, and alterations of the bile and pancreatic ducts.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"18 2","pages":"198-203"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/09/PG-18-47490.PMC10395057.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9935790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Colon cancer is a major public health issue, affecting a growing number of individuals worldwide. Proper and early diagnosis of colon cancer is the necessary first step toward effective treatment and/or prevention of future disease relapse. Artificial intelligence and its subtypes, deep learning in particular, tend nowadays to have an expanding role in all fields of medicine, and diagnosing colon cancer is no exception. This report aims to summarize the entire application spectrum of deep learning in all diagnostic tests regarding colon cancer, from endoscopy and histologic examination to medical imaging and screening serologic tests.
{"title":"The role of deep learning in diagnosing colorectal cancer.","authors":"Dimitrios Bousis, Georgios-Ioannis Verras, Konstantinos Bouchagier, Andreas Antzoulas, Ioannis Panagiotopoulos, Anastasia Katinioti, Dimitrios Kehagias, Charalampos Kaplanis, Konstantinos Kotis, Christos-Nikolaos Anagnostopoulos, Francesk Mulita","doi":"10.5114/pg.2023.129494","DOIUrl":"10.5114/pg.2023.129494","url":null,"abstract":"<p><p>Colon cancer is a major public health issue, affecting a growing number of individuals worldwide. Proper and early diagnosis of colon cancer is the necessary first step toward effective treatment and/or prevention of future disease relapse. Artificial intelligence and its subtypes, deep learning in particular, tend nowadays to have an expanding role in all fields of medicine, and diagnosing colon cancer is no exception. This report aims to summarize the entire application spectrum of deep learning in all diagnostic tests regarding colon cancer, from endoscopy and histologic examination to medical imaging and screening serologic tests.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"1 1","pages":"266-273"},"PeriodicalIF":1.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70475065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}